Skip to main content

CRO Event: Evaluating Your Therapeutics’ Performance Against Diet-induced NAFLD/NASH Models

When:

October 15, 2019 8:00 amOctober 15, 2019 10:00 am (PDT)

Where:

Biocom – McGraw Conference Room
10996 Torreyana Road Suite 200
San Diego, California 92121

Registration Closed

Are you evaluating your therapeutics' performance against diet-induced NAFLD/NASH models? Are you in search of a timely preclinical solution that can generate high-quality data for quick go/no-go decision making?

With a global upswing in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with no readily available, FDA-approved therapeutic, many companies have prioritized NAFLD/NASH-related studies in hopes of expediting successful drug launches.

At this event, our expert panel will discuss commercially available in vivo mouse models and their related study design. Specific experimental procedures used to induce the desired disease phenotype will be explained in detail; and an actual case study data will be presented. In addition to in vivo procedures, our panelists will also discuss histological analysis of the liver pathology.

Panelists:
Dr. Manindra Singh, Preclinical Scientist, Explora BioLabs
Janell Richardson, Field Application Specialist, Taconic
Aruna Somasiri, President and CEO, Wax-It Histology Services, Inc.

Price of Admission

Biocom Member

Today’s Price: 0

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

0

Refund before 2019-10-14

0

Refund before

Refund Before

Non-Member (Industry Only)

Today’s Price: 30

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

30

Refund before 2019-10-14

30

Refund before

Refund Before

Registration Closed